Sikic Laboratory Publications

Featured publications from our laboratory (2004-15):

  • Advani R, Peethambaram P, Lum BL, Fisher GA, Hartmann L, Long HJ, Halsey J, Holmlund JT, Dorr A, and Sikic BI. A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer 100: 321-6, 2004. 
  • Genomics-based hypothesis generation: a novel approach to unravelling drug resistance in brain tumours? Lancet Oncology 5: 89-100, 2004. 
  • Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum BL, Chin DL, Dewald G, Paietta E, Bennett JM, and Rowe JM. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol. 22: 1078-86, 2004.
  • Chen GK, Sale S, Tan T, Ermoian RP, and Sikic BI. CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAATT box in human cancer cells. Mol Pharmacol. 65: 906-16, 2004. 
  • Lacayo NJ, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM, Douglas L, Wahab R, Becton DL, Weinstein H, Chang MN, Willman CL, Radich JP, Tibshirani R, Ravindranath Y, Sikic BI, and Dahl GV. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood 104: 2646-54, 2004.
  • Tu IP, Schaner M, Diehn M, Sikic BI, Brown PO, Botstein D, and Fero MJ. A method for detecting and correcting feature misidentification on expression microarrays. BMC Genomics 5: 64, 2004.
  • Dumontet C, Jaffrezou J-P, Tsuchiya E, Duran GE, Chen G, Derry WB, Wilson L, Jordan MA, and Sikic BI. Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant with altered tubulin expression and polymerization.Bull Cancer91: E81-112, 2004.
  • Bredel M, Bredel C, Juric D, Kim Y, Vogel H, Harsh GR, Recht LD, Pollack JR and Sikic. Amplification of whole tumor genomes and gene-by-gene mapping of genomic aberrations from limited sources of fresh-frozen and paraffin-embedded DNA. J Mol Diagn 7: 171-82, 2005.
  • Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, and Sikic BI. High-resolution genome-wide mapping of genetic alterations in human glial brain tumors. Cancer Res 65: 4088-96, 2005. 
  • Kuo T, Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, Fisher GA, Sikic BI. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol 23(24): 5446-9, 2005. 
  • Advani R, Lum BL, Fisher GA, Halsey J, Chin DL, Jacobs CD, Sikic BI. A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. Annals of Oncology 16: 1968-1973, 2005.
  • Advani, R, Lum BL, Fisher GA, Halsey J, Geary RS, Holmlund JT, Kwoh TJ, Dorr FA, Sikic BI. A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer.Investigational New Drugs 23: 467-477, 2005. 
  • Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res 65(19): 8679-89, 2005.
  • Chen KG, Wang YC, Schaner ME, Francisco EB, Duran GE, Juric D, Huff LM, Padilla-Nash H, Ried T, Fojo T, Sikic BI. Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line. Cancer Res 65(20): 9388-97, 2005.
  • Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC, Head DR, Stine KC, Lacayo NJ, Sikic BI, Arceci RJ, Weinstein H, Pediatric Oncology Group. Randomized use of cyclosporinn A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood 107(4): 1315-24, 2006.
  • Juric D, Sale S, Hromas RA, Yu R, Wang Y, Duran GE, Tibshirani R, Einhorn LH, Sikic BI. Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures. Proc Natl Acad Sci USA 102(49): 17763-8, 2005. 
  • Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harsh GR, Vogel H, Recht LD, Scheck AC, Sikic BI. Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. 
  • Wang YC, Juric D, Francisco EB, Yu RX, Duran GE, Chen GK, Chen X, Sikic BI. Regional activation of chromosal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines. Genes Chromosomes Cancer 45(4): 365-74, 2006. 
  • DiMartino JF, Lacayo NJ, Varadi M, Li L, Saraiya C, Ravindranath Y, Yu R, Sikic BI, Raimondi SC, Dahl GV. Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia 20(3): 426-32, 2006.
  • Cho CD, Fisher GA, Halsey J, Sikic BI. Phase I study of gefitinib, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies. Invest New Drugs 24(2): 117-23, 2006.
  • Sikic BI. Multidrug resistance and stem cells in acute myeloid leukemia. Clin Cancer Res 12(11): 3231-2, 2006. 
  • Carlson RW, O'Neill AM, Goldsteinn LJ, Sikic BI, Abramson N, Stewart JA, Davidson NE, Wood WC, Eastern Cooperative Oncology Group. A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metatstatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group. Cancer Invest 24(7): 677-81, 2006. 
  • Juric D, Lacayo NJ, Ramsey MC, Racevskis J, Wiernik PH, Rowe JM, Goldstone AH, O'Dwyer PJ, Paietta E, Sikic BI. Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. J Clin Oncol 25(11): 1341-9, 2007.
  • Juric D, Bredel C, Sikic BI, Bredel M. Integrated high-resolution genome-wide analysis of gene dosage and gene expression in human brain tumors. Methods Mol Biol 377: 187-202, 2007.
  • Chan JK, Ueda SM, Sugiyama VE, Stave CD, Shin JY, Monk BJ, Sikic BI, Osann K, Kapp DS. J Clin Oncol 26(9): 1511-8, 2008.
  • Sikic BI, Tibshirani R, Lacayo NJ. Genomics of childhood leukemias: the virtue of complexity. J Clin Oncol 26(27): 4367-8, 2008.
  • Marcelleti JF, Multani PS, Lancet JE, Baer MR, Sikic BI. Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trail of zosuquidar infusion in acute myeloid leukemia. Leuk Res 33(6): 769-74, 2009.
  • Fisher GA, Kuo T, Ramsey M, Schwartz E, Rouse RV, Cho CD, Halsey J, Sikic BI. A phase II study of gefitinib 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colon cancer. Clin Cancer Res 14(21): 7074-9, 2008.
  • Lancet JE, Baer MR, Duran GE, List AF, Fielding R, Marcelleti JF, Multani PS, Sikic BI. A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. Leuk Res 33(8): 1055-61, 2009.
  • Bredel M, Scholtens, DM, Harsh GR, Bredel C, Chandler JP, Renfrow JJ, Yadav AK, Vogel H, Scheck AC, Tibshirani R, Sikic BI. A network model of a cooperative genetic landscape in brain tumors. JAMA 302(3): 261-75, 2009.
  • Yadav AK, Renfrow JJ, Scholtens DM, Xie H, Duran GE, Bredel C, Vogel H, Chandler JP, Chakravarti A, Robe PA, Das S, Scheck AC, Kessler JA, Soares MB, Sikic BI, Harsh GR, Bredel M. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas. JAMA 302(3): 276-89, 2009.
  • Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R, Ullrich SJ, Fisher GA, Tolcher AW. Phase I and pharmacokinetic study of lexatumumab (HGB-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol 21(2): 376-81, 2010.
  •  O'Brien MM, Lacayo NJ, Lum BL, Kshirsagar S, Buck S, Ravindranath Y, Bernstein M, Weinstein H, Chang MN, Arceci RJ, Sikic BI, Dahl GV. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 54(5): 694-702, 2010.
  • Galatin PS, Advani RH, Fisher GA, Francisco B, Julian T, Losa R, Sierra MI, Sikic BI. Phase I trial of oblimersen (Genasense) and gemcitabine in refractory and advanced malignancies. Invest New Drugs 29(5): 971-7, 2011.
  • Spicakova T, O'Brien MM, Duran GE, Sweet-Cordero A, Sikic BI. Expression and silencing of the microtubule-associated protein Tau in breast cancer cells. Mol Cancer Ther 9(11): 2970-81, 2010.
  • Bredel M, Scholtens DM, Yadav AK, Alvarez AA, Renfrow JJ, Chandler JP, Yu IL, Carro MS, Dai F, Tagge MJ, Ferrarese R, Bredel C, Phillips HS, Lukac PJ, Robe PA, Weyerbrock A, Vogel H, Dubner S, Mobley B, He X, Scheck AC, Sikic BI, Aldape KD, Chakravarti A, Harsh GR 4th. NFKB1A deletion in glioblastomas. N Engl J Med 364(7): 627: 37, 2011.
  •  Cabebe EC, Fisher GA, Sikic BI. A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. Invest New Drugs 30(3): 1082-7, 2012.
  • Kunz PL, He AR, Colevas AD, Pishvaian MJ, Hwang JJ, Clemens PL, Messina M, Kaleta R, Abrahao F, Sikic BI, Marshall JL. Phase I trial of ixabepilone adminstered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. Invest New Drugs 30(6): 2364-70 2012.
  • Chen KG, Sikic BI. Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin Cancer Res 18(7): 1863-9, 2012.
  • Lai TL, Lavori PW, Shih MC, Sikic BI. Clinical trial designs for testing biomarker-based personalized therapies. Clin Trials 9(2): 141-54, 2012.
  • Gevaert O, Villalobos V, Sikic BI, Plevritis SK. Identification of ovarian cancer driver genes by using module network integration of multi-omics data. Interface Focus 3(4): 2013.
  • Moisan F, Francisco EB, Brozovic A, Duran GE, Wang YC, Chaturvedi S, Seetharam S, Snyder LA, Doshi P, Sikic BI. Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers. Mol Oncol 8(7): 1231-9, 2014.
  • Smith DC, Eisenberg PD, Manikhas GM, Chugh R, Gubens MA, Stagg RJ, Kapoun AM, Xu L, Dupont J, Sikic BI. A phase I dose escalation and expansion study of the anti-cancer stem cell agent demcizumab (Anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res 20(24), 2014.
  • Duran GE, Wang YC, Francisco EB, Rose JC, Martinez FJ, Coller J, Brassard D, Vrignaud P, Sikic BI. Mechanisms of resistance to cabazitaxel. Mol Cancer Ther 14(1), 2015.